PT  - JOURNAL ARTICLE
AU  - ACTIV-3/TICO Bamlanivimab Study Group
AU  - Jens D. Lundgren
AU  - Birgit Grund
AU  - Christina E. Barkauskas
AU  - Thomas L. Holland
AU  - Robert L. Gottlieb
AU  - Uriel Sandkovsky
AU  - Samuel M. Brown
AU  - Kirk U. Knowlton
AU  - Wesley H. Self
AU  - D. Clark Files
AU  - Mamta K. Jain
AU  - Thomas Benfield
AU  - Michael E. Bowdish
AU  - Bradley G. Leshnower
AU  - Jason V. Baker
AU  - Jens-Ulrik Jensen
AU  - Edward M. Gardner
AU  - Adit A. Ginde
AU  - Estelle S. Harris
AU  - Isik S. Johansen
AU  - Norman Markowitz
AU  - Michael A. Matthay
AU  - Lars Østergaard
AU  - Christina C. Chang
AU  - Anna Goodman
AU  - Weizhong Chang
AU  - Robin L. Dewar
AU  - Norman P. Gerry
AU  - Elizabeth S. Higgs
AU  - Helene Highbarger
AU  - Daniel D. Murray
AU  - Thomas A. Murray
AU  - Ven Natarajan
AU  - Roger Paredes
AU  - Mahesh K.B. Parmar
AU  - Andrew N. Phillips
AU  - Cavan Reilly
AU  - Adam W. Rupert
AU  - Shweta Sharma
AU  - Kathryn Shaw-Saliba
AU  - Brad T. Sherman
AU  - Marc Teitelbaum
AU  - Deborah Wentworth
AU  - Huyen Cao
AU  - Paul Klekotka
AU  - Abdel G. Babiker
AU  - Victoria J. Davey
AU  - Annetine C. Gelijns
AU  - Virginia L. Kan
AU  - Mark N. Polizzotto
AU  - B. Taylor Thompson
AU  - H. Clifford Lane
AU  - James D. Neaton
TI  - Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
AID  - 10.1101/2021.07.19.21260559
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.19.21260559
4099  - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260559.short
4100  - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260559.full
AB  - BACKGROUND Bamlanivimab, a neutralizing monoclonal antibody given in combination with remdesivir, did not improve outcomes among hospitalized COVID-19 patients based on an early futility assessment. In this final study report, we evaluate an a priori hypothesis that greater benefit of bamlanivimab would be identified in those without detectable endogenous neutralizing antibody levels at study entry, especially if viral levels were high.METHODS Hospitalized COVID-19 patients were randomized to receive bamlanivimab (7000mg) or placebo and followed for 90 days for sustained recovery (home for 14 consecutive days); recovery rate ratios (RRRs) are cited.RESULTS Among 314 participants (163 on bamlanivimab and 151 on placebo), the median time to sustained recovery was 19 days and RRR=0.99 (95% CI: 0.79-1.22; p=0.89). At entry, 50% evidenced production of anti-spike neutralizing antibodies; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels ≥ 1,000 ng/L. Among those without and with antibodies at study entry, the RRRs were 1.24 (95% CI: 0.90-1.70) and 0.74 (95% CI: 0.54-1.00) (p=0.02 for interaction). The RRRs were elevated for those with plasma antigen or nasal viral RNA levels above versus below median at entry, and was greatest for those without antibodies and with elevated antigen or viral RNA levels: 1.48 (95% CI: 0.99-2.23), 1.94 (1.25-3.00), respectively (p<0.05 for all interactions). Hazard ratios for safety outcomes also differed by serostatus at entry.CONCLUSIONS Sustained recovery after administration of bamlanivimab versus placebo differed by presence of neutralizing antibodies at study entry, especially if participants had markers of elevated viral replication.ClinicalTrials.gov number, NCT04501978.Competing Interest StatementMixed competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; AGB has received research grants from the University of Minnesota, USA and the Medical Research Council, UK, AAG has received a research grant from NHLBI, ACG has received research grants from the NIH, BTT has received research grants from NHLBI, Birgit Grund has received research grants from the NIH, DCF has received research grants from the NIH and reports personal fees from Cytovale outside the submitted work, EMG has received research grants from NIAID, HC reports other from Gilead Sciences, outside the submitted work, JDN has received research grants from NIH and NIAID, LO reports personal fees from a lecture given at Gilead Sciences in 2008 outside the submitted work, MKJ reports grants and personal fees from Gilead Sciences and grants from Regeneron outside the submitted work, MAM reports grants from Roche-Genentech, personal fees from Novartis Pharmaceuticals, personal fees from Citius Pharmaceuticals, grants from Department of Defense, grants from NIH/NHLBI, grants from California Institute of Regenerative Medicine, outside the submitted work, PK reports personal fees from Eli Lilly, during the conduct of the study; personal fees from Eli Lilly, outside the submitted work, RLG reports personal fees and non-financial support from Gilead Sciences, Inc., outside the submitted work, RP reports grants and personal fees from Gilead, grants and personal fees from MSD, grants and personal fees from ViiV Healthcare, outside the submitted work, SMB reports grants from NIH, during the conduct of the study; personal fees from Hamilton, other from Faron, other from Sedana, grants from Janssen, grants from NIH, grants from DoD, other from Oxford University, other from Brigham Young University, personal fees from NYU, outside the submitted work, SS reports grants from NIH, during the conduct of the study, TLH reports personal fees from Basilea Pharmaceutica (ceftobiprole), personal fees from Motif Bio (iclaprim), personal fees from Genentech (immunotherapeutic), outside the submitted work, TB reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, outside the submitted work, US reports grants from National Institutes of Health, during the conduct of the study; grants from Regeneron, grants from National Institues of Health, grants from Cytodyn, outside the submitted work, WHS reports grants from National Heart, Lung, and Blood Institute, during the conduct of the study; personal fees from Aerpio Pharmaceuticals, outside the submitted work.Clinical TrialNCT04501978Funding StatementThe trial was primarily funded by Operation Warp Speed, with the support of NIAID, NIH Grant U01-AI136780, and the Division of Clinical Research and Leidos Biomedical Research, Inc., Contract HHSN261200800001E, for the INSIGHT Network, and NHLBI and the Research Triangle Institute for the PETAL and CTSN Networks. Other funding and support was provided by the U.S. Departments of Veterans Affairs, and the governments of Denmark (National Research Foundation; grant no 126), Australia (National Health and Medical Research Council), and U.K. (Medical Research Council, MRC_UU_12023/23). Study medications were donated by Gilead Sciences, and Eli Lilly.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following ethics committees approved the TICO protocol for the Bamlanivimab part of the study (protocol v1.0): US: central IRB- Advarra UK: South Central - Berkshire Research Ethics Committee Greece: Hellenic Republic, Minister of Health and Welfare, National Ethic Committee Uganda: The Uganda Virus Research Institute Research and Ethics Committee Singapore: National Healthcare Group Domain-Specific Review Board Denmark: De Videnskabsetiske Komiteer for Region Hovedstaden Spain: Comite d Etica de la Investigacio amb medicaments, Hospital Universitari Germans Trias i Pujol Poland: Komisja Bioetyczna przy Uniwersytecie Warszawskim At the time of discontinuation of the Bamlanivimab part of the TICO study, no other IRB disapproved of the study or waived approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data set used for this manuscript is available upon request to the INSIGHT scientific steering committee at insightsscsec.rigshospitalet{at}regionh.dk